Treatment of Autism Spectrum Disorders by Mitochondrial-targeted Drug: Future of Neurological Diseases Therapeutics
Open Access
- 1 May 2023
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 21 (5) , 1042-1064
Abstract
S: Autism is a neurodevelopmental disorder with a complex etiology that might involve environmental and genetic variables. Recently, some epidemiological studies conducted in various parts of the world have estimated a significant increase in the prevalence of autism, with 1 in every 59 children having some degree of autism. Since autism has been associated with other clinical abnormalities, there is every possibility that a sub-cellular component may be involved in the progression of autism. The organelle remains a focus based on mitochondria's functionality and metabolic role in cells. Furthermore, the mitochondrial genome is inherited maternally and has its DNA and organelle that remain actively involved during embryonic development; these characteristics have linked mitochondrial dysfunction to autism. Although rapid stride has been made in autism research, there are limited studies that have made particular emphasis on mitochondrial dysfunction and autism. Accumulating evidence from studies conducted at cellular and sub-cellular levels has indicated that mitochondrial dysfunction's role in autism is more than expected. The present review has attempted to describe the risk factors of autism, the role of mitochondria in the progression of the disease, oxidative damage as a trigger point to initiate mitochondrial damage, genetic determinants of the disease, possible pathogenic pathways and therapeutic regimen in vogue and the developmental stage. Furthermore, in the present review, an attempt has been made to include the novel therapeutic regimens under investigation at different clinical trial stages and their potential possibility to emerge as promising drugs against ASD.Keywords
This publication has 207 references indexed in Scilit:
- The Hallmarks of AgingCell, 2013
- Altered T cell responses in children with autismBrain, Behavior, and Immunity, 2011
- Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disordersJournal of Neuroimmunology, 2011
- Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysisMolecular Psychiatry, 2011
- Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcomeBrain, Behavior, and Immunity, 2011
- Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuliEMBO Molecular Medicine, 2010
- Differential monocyte responses to TLR ligands in children with autism spectrum disordersBrain, Behavior, and Immunity, 2010
- Mitochondria, calcium and cell death: A deadly triad in neurodegenerationBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- Immune transcriptome alterations in the temporal cortex of subjects with autismNeurobiology of Disease, 2008
- Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autismAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006